Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Pfizer Deal Speeds Up, Aurobindo Tangos With AstraZeneca For Branded Generics Play In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's Aurobindo Pharma is turning out to be a partner of choice for Big Pharma companies that intend to dig aggressively into emerging markets with a branded generics product portfolio

You may also be interested in...



Soriot Effect Sees AstraZeneca Selectively Scale Back Branded Generics In Emerging Markets

Leadership change is forcing the Anglo-Swedish drug giant to review its priorities in the branded generics business. AstraZeneca will invest selectively in countries where it has built a high base and shows ability to post robust growth.

With A New CEO, Will AstraZeneca Change Its Approach In Emerging Markets?

Roche’s surging growth in China could hint at what’s coming to AstraZeneca in emerging markets as Pascal Soriot, Roche’s head of pharmaceuticals, takes over at AZ.

AstraZeneca, Lilly, Novo Look To China Growth Despite Pricing Headwinds – Emerging Market Earnings Roundup (Part 1)

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC076088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel